Thomsen–Friedenreich antigen
 | This article needs more links to other articles to help integrate it into the encyclopedia. (November 2012) |
Thomsen–Friedenreich antigen (Galβ1-3GalNAcα1) is a disaccharide.[1] It is usually present on cell surfaces in a cryptic form covered by [2] N-acetyl neuraminic acid moieties and released into circulation in many different cancers.[citation needed]
See also
Abstract The Thomsen–Friedenreich antigen (Gal-GalNAc) represents a tumor-associated molecule, which is assumed to be one of the few chemically well-defined antigens with a proven association with malignancy. In order to analyze the role of the carbohydrate structure Gal-GalNAc for gastrointestinal tumors, we immunized Balb/c mice with MCF-7 breast tumor cells together with synthetic Gal-GalNAc linked to a BSA carrier. One monoclonal antibody (82-A6) was established which recognizes the Thomsen–Friedenreich antigen according to the biochemical and serological analysis presented here. In contrast to the studies performed in the past, immunohistochemical results using this antibody 82-A6 did not exhibit a reactivity clearly restricted to tumors. Preliminary biochemical analysis revealed that the T-determinant is detectable in the high-molecular weight range (about 1000 kD), suggesting that the Gal-GalNAc epitope is found on mucinlike glycoproteins. Tumor restriction of Thomsen–Friedenreich antigen may therefore be determined either by the protein backbone or by the beta-glycosidic linkage of the carbohydrate structure to the protein. As sited on: Dippold, W; Steinborn, A; Meyer; Büschenfelde, KH (August 1990). "The role of the Thomsen-Friedenreich antigen as a tumor-associated molecule". Environ. Health Perspect. 88: 255–7. doi:10.2307/3431086. PMC 1568008. PMID 2272320.
References
- ^ Yu, Lu-Gang (2007). "The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression". Glycoconjugate Journal. 24 (8): 411–20. doi:10.1007/s10719-007-9034-3. PMID 17457671.
- ^ http://pedsccm.org/RARE/HUS.html[unreliable medical source?]
External links
- Dippold, W.; Steinborn, A.; Büschenfelde, K. H. M. z. (1990). "The Role of the Thomsen-Friedenreich Antigen As a Tumor-Associated Molecule". Environmental Health Perspectives. 88: 255–7. doi:10.2307/3431086. PMC 1568008. PMID 2272320.
- King, MJ; Holburn, AM (1979). "Radioassays of blood group M, N and T (Thomsen-Friedenreich) antigens". Immunology. 38 (1): 129–36. PMC 1457886. PMID 511213.
- Singh, R.; Campbell, BJ; Yu, LG; Fernig, DG; Milton, JD; Goodlad, RA; Fitzgerald, AJ; Rhodes, JM (2001). "Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44". Glycobiology. 11 (7): 587–92. doi:10.1093/glycob/11.7.587. PMID 11447138.
- Wolf, Michael F.; Koerner, Ulrike; Schumacher, Kurt (1986). "Specificity of reagents directed to the Thomsen-Friedenreich antigen and their capacity to bind to the surface of human carcinoma cell lines". Cancer Research. 46 (4 Pt 1): 1779–82. PMID 2418954.
- Uhlenbruck, G. (1981). "The Thomsen-Friedenreich (TF) Receptor: An Old History with New Mystery". Immunological Investigations. 10 (3): 251–64. doi:10.3109/08820138109093459. PMID 7037612.
.svg){kind=small} | This biochemistry article is a stub. You can help Wikipedia by expanding it. |